Overcoming intrinsic and acquired cetuximab resistance: an in vitro study on the potential of afatinib in HNSCC cell lines

被引：0
|
作者：
De Pauw, Ines
Wouters, An
Van den Bossche, Jolien
Deschoolmeester, Vanessa
Pauwels, Patrick
Vermorken, Jan B.
Peeters, Marc
Lardon, Filip
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-4102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4102
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Presence of amphiregulin autocrine-loop predicts in vitro sensitivity of EGFR wild type NSCLC and HNSCC cell lines to gefitinib and cetuximab
    Yonesaka, Kimio
    Zejnullahu, Kreshnik
    Homes, Alison J.
    Johnson, Bruce E.
    Janne, Pasi A.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S382 - S382
  • [32] Overcoming EGFR Resistance Using Dasatinib in Combination with Cetuximab and Cisplatin in Triple Negative Breast Cancer Cell Lines.
    Kim, E. M. H.
    Gartner, E.
    Choi, L.
    Boerner, J.
    CANCER RESEARCH, 2011, 71
  • [33] Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines
    Haymerle, Georg
    Thurnher, Dietmar
    Kadletz, Lorenz
    Stanisz, Isabella
    Brunner, Markus
    Kotowski, Ulana
    Enzenhofer, Elisabeth
    Heiduschka, Gregor
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2015, 272 (11) : 3451 - 3456
  • [34] Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib
    Horn, Leora
    Gettinger, Scott
    Camidge, D. Ross
    Smit, Egbert F.
    Janjigian, Yelena Y.
    Miller, Vincent A.
    Pao, William
    Freiwald, Matthias
    Fan, Jean
    Wang, Bushi
    Chand, Vikram K.
    Groen, Harry J. M.
    LUNG CANCER, 2017, 113 : 51 - 58
  • [35] Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines
    Georg Haymerle
    Dietmar Thurnher
    Lorenz Kadletz
    Isabella Stanisz
    Markus Brunner
    Ulana Kotowski
    Elisabeth Enzenhofer
    Gregor Heiduschka
    European Archives of Oto-Rhino-Laryngology, 2015, 272 : 3451 - 3456
  • [36] AKT IS A POTENTIAL TARGET FOR OVERCOMING ACQUIRED RESISTANCE TO TYROSINE KINASE INHIBITORS IN RENAL CELL CARCINOMA
    Harada, Ken-ichi
    Miyake, Hideaki
    Fujisawa, Masato
    JOURNAL OF UROLOGY, 2013, 189 (04): : E66 - E67
  • [37] Resistance to cetuximab -: implication of PTEN expression in the cellular sensitivity to cetuximab (Erbitux®) of Head and Neck Squamous Cell Carcinoma (HNSCC)
    Mriouah, J.
    Chartier, C.
    Boura, C.
    Fifre, A.
    Fries, I.
    Ramacci, C.
    Merlin, J. L.
    Faivre, B. M. A.
    EJC SUPPLEMENTS, 2008, 6 (09): : 112 - 112
  • [38] Intrinsic and acquired trastuzumab resistance pathways in breast cancer cell lines using DigiWest® phosphoprotein profiling
    Scerri, Jeanesse
    Ruoff, Felix
    Templin, Markus
    Grech, Godfrey
    Scerri, Christian
    CANCER RESEARCH, 2020, 80 (16)
  • [39] Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1
    Pirazzoli, Valentina
    Nebhan, Caroline
    Song, Xiaoling
    Wurtz, Anna
    Walther, Zenta
    Cai, Guoping
    Zhao, Zhongming
    Jia, Peilin
    de Stanchina, Elisa
    Shapiro, Erik M.
    Gale, Molly
    Yin, Ruonan
    Horn, Leora
    Carbone, David P.
    Stephens, Philip J.
    Miller, Vincent
    Gettinger, Scott
    Pao, William
    Politi, Katerina
    CELL REPORTS, 2014, 7 (04): : 999 - 1008
  • [40] Receptor tyrosine kinase plasticity as a mechanism of acquired resistance to cetuximab in vitro: potential for co-targeting with antibody mixtures
    Kjaer, Ida
    Kragh, Michael
    Horak, Ivan D.
    Pedersen, Mikkel Wandahl
    CANCER RESEARCH, 2013, 73 (08)
12345